Drug Trial Radar · NCT00051012
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
Last checked: Nov 20, 2026Latest source record: Mar 5, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Sep 1995
Primary completion
Oct 2006
Study completion Dec 2006
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Jan 3, 2003
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ONTAK. It is also designed to determine the effectiveness of ONTAK in Cutaneous T-cell Lymphoma (CTCL) patients whose tumors do not express CD25.
Conditions
- Lymphoma, T-Cell, Cutaneous
- Mycosis Fungoides
- Sezary Syndrome
Interventions
ONTAKDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Rate of Response (ORR), defined as CR + CCR + PR
Locations
34 sites in 9 countries. Site status is shown where the registry gives one.
University of Texas, M.D. Anderson Cancer Center
Houston, Texas
Level 4 Department of Haematology Royal North Shore Hospital
Saint Leonard's, New South Wales, Australia
Westmead Hospital, Department of Haematology
Westmead, New South Wales, Australia
Mater Misericordiae Adult Hospital
South Brisbane, Queensland, Australia
Oncology Haematology Radiation Oncology Unit, Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Peter MacCallum Cancer Institute
Melbourne, Victoria, Australia
LKH Universitatsklinikum Graz
Graz, Austria
Allgemeines Krankenhaus der Stadt Wien
Vienna, Austria
Cross Cancer Centre
Edmonton, Alberta, Canada
Hamilton Regional Cancer Center
Hamilton, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Universitatsklinikum Charite
Berlin, Germany
University of Erlangen
Erlangen, Germany
Universitatsklinikum Essen
Essen, Germany
J.W. Goethe University Frankfurt
Frankfurt, Germany
Universitatskrankenhaus Eppendorf
Hamburg, Germany
Universitatsklinikum Mannheim
Mannheim, Germany
Universitatsklinikum Munster
Münster, Germany
Medical Academy in Gdansk, Dept. of Hematology
Gdansk, Poland
Regional Oncological Center, Dept. of Chemotherapy
Lodz, Poland
Klinika Hematoonkologii Akademii Medycznej w Lublinie
Lublin, Poland
Oddzial Chorob Wewnetrznych i Hematologii
Poznan, Poland
The Medical University of Warsaw, Central Clinical Hospital
Warsaw, Poland
Centrum Onkologii-Instytut im. Marii Sklodoskiej-Curie
Warsaw, Poland
Blokhin Russian Cancer Research Center, RAMS
Moscow, Russia
Burdenko Main Military Clinical Hospital
Moscow, Russia
Central Research Institute of Skin and Venereal Diseases
Moscow, Russia
Haematology Research Center RAMS
Moscow, Russia
St. Petersburg Pavlov State Medical University
Saint Petersburg, Russia
Samara Regional Clinical Hospital
Samara, Russia
Universitatsspital Zurich Dermatologische Klinik
Zurich, Switzerland
St. John's Institute of Dermatology
London, United Kingdom
City Hospital
Nottingham, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.